With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so ...

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

New members of the Advisory Committee on Immunization Practices have not yet been identified, but they are expected to meet later this month. Separately, the FDA has approved Merck's monoclonal ...

China's center for drug evaluation will assess an application to market Merck's KGaA's tumor treatment pimicotinib in the country, the company said. The German life-sciences and electronics company ...